Ischemic Heart Disease
Pipeline by Development Stage
Drug Modality Breakdown
On Market (1)
Approved therapies currently available
Competitive Landscape
22 companies ranked by most advanced pipeline stage
Trial Timeline
Clinical trial activity over time
Showing 15 of 36 trials with date data
Clinical Trials (36)
Total enrollment: 20,190 patients across 36 trials
Development of a PET-MR Myocardial Perfusion Examination Using Regadenoson
PIONIR Study (Presillion™ and Presillion™ Plus Stent Systems)
Randomized Study Comparing Endeavor With Cypher Stents (PROTECT)
EWISE: Study of Eplerenone in Women With Chest Pain, Coronary Vascular Dysfunction and Evidence of Myocardial Ischemia
Celecoxib, Ibuprofen and the Antiplatelet Effect of Aspirin
Acute Safety, Deliverability and Efficacy of the Medtronic Resolute Integrity™ Zotarolimus-Eluting Coronary Stent System in the Treatment of Suitable Patients According to Indication for Use (CHINA RESOLUTE INTEGRITY STUDY)
Chaigui Longmu Ejiao Paste for Ischemic Heart Disease
Safety and Efficacy Study of Gene Therapy for Acute Myocardial Infarction in Korea
GS-6615 in Adults With Chronic Stable Angina and Coronary Artery Disease
Autologous Cell Therapy for Ischemic Heart Failure
Safety Study of Gene Therapy for Ischemic Heart Disease in Korea
Can Changes in Velocity Time Integral Serve as a Sensitive Indicator for Monitoring Changes in Stroke Volume ?
A Phase 1 Study to Assess the Safety,Tolerability, and Pharmacokinetics of GS-6615 in Healthy Subjects
Myocardial Perfusion Magnetic Resonance Imaging Using Regadenoson
Optical Coherence Tomography in Acute Vessel Evaluation
Impact of Dynamic CoROnary RoADmap System for Guidance of Instantaneous Wave-Free Ratio or Fractional Flow Reserve
Dose Optimization for Rubidium PET Imaging in Patients With Known or Suspected Ischemic Heart Disease
BIOFLOW-SV Portugal Registry
RESOLUTE ONYX China RCT Study
RESOLUTE ONYX China Single Arm Study
ABSORB Post-Approval Clinical Study
China Resolute Integrity 34/38 mm Study
StEnt Coverage and Neointimal Tissue Characterization After eXtra Long evErolimus - Eluting Stent imPlantation
Early Prediction of Major Adverse Cardiovascular Events Using Remote Monitoring
Absorb GT1 Japan PMS
Registry in Korea: BioMimeTM Stent, Ultimaster® Stent vs. Xience® Stent
XIENCE Xpedition Everolimus-Eluting Coronary Stent Japan Post Marketing Surveillance (XIENCE Xpedition SV Japan PMS)
XIENCE PRIME SV Everolimus Eluting Coronary Stent Japan Post Marketing Surveillance (XIENCE PRIME SV Japan PMS)
RESOLUTE China RCT
RESOLUTE China Registry:
A Clinical Evaluation of the MINI TREK RX 1.20 mm Coronary Dilatation Catheter in Stenotic Lesions
Comparison Between Everolimus-eluting Stent (EES) and Sirolimus-eluting Stent (SES) in the Bifurcation Lesion
RESOLUTE Asia: Evaluation of the Endeavor Resolute Zotarolimus-Eluting Stent System in a Patient Population With Long Lesion(s) and/or Dual Vessels in Asia
AnalyST Treadmill Study
The Israeli MGuard Registry
Using Duke Activity Status Index (DASI) to Select Optimal Cardiac Stress Tests
Related Jobs
Application Security Engineer
Senior Software Engineer
Staff Software Engineer
Staff Data Scientist
Marketing Communications Manager
Senior Software Engineer - Backend
Phase Legend
Key Insights
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.